The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Merck (NYSE:MRK) reported a series of positive late stage clinical trial results for oncology and HIV therapies, including ...

Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination ...

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

(Reuters) -Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

The winners will not be those who merely predict cliffs, but those who re-architect early enough. Merck’s oncology spin-out underscores a defining reality of modern pharma: molecules may create value, ...

Merck (NYSE:MRK) reported multiple positive Phase 3 results for KEYTRUDA-based combinations in renal cell carcinoma, bladder ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...